Observational study of Mcm5 in bladder cancer patients.
Research type
Research Study
Full title
Observational study of urinary Mcm5 levels in newly diagnosed bladder cancer patients undergoing therapy and surveillance - Identifying optimal sample collection, effect of tumour resection and intravesical therapy, variation prior to therapy and role in detection of recurrence.
IRAS ID
179810
Contact name
Tim Dudderidge
Contact email
Sponsor organisation
University Hospital Southampton
Duration of Study in the UK
0 years, 5 months, 28 days
Research summary
Research has shown that detection of Mcm5 in urine sediment is a sensitive and specific diagnostic test for bladder cancer.The study will collect urine samples from patients undergoing treatment for bladder cancer at Southampton General Hospital. The urine will be tested for the Mcm5 protein. This observational study will seek to chart the natural history of Mcm5 from initial presentation and throughout the course of treatment. The objective is to assess optimal sample collection, the potential utility of the Mcm5 assay for monitoring disease, measuring response to therapy and the detection of recurrence of disease. The study will not seek to prove any relationships between bladder cancer treatment and recurrence and Mcm5 but will instead aim to identify trends in individual patients and develop hypotheses for future research.
REC name
London - Chelsea Research Ethics Committee
REC reference
15/LO/1695
Date of REC Opinion
24 Sep 2015
REC opinion
Favourable Opinion